<SEC-DOCUMENT>0001104659-24-109381.txt : 20241017
<SEC-HEADER>0001104659-24-109381.hdr.sgml : 20241017
<ACCEPTANCE-DATETIME>20241017081118
ACCESSION NUMBER:		0001104659-24-109381
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241017
DATE AS OF CHANGE:		20241017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XORTX Therapeutics Inc.
		CENTRAL INDEX KEY:			0001729214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269429
		FILM NUMBER:		241375949

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
		BUSINESS PHONE:		403-607-2621

	MAIL ADDRESS:	
		STREET 1:		SUITE 2400 - 745 THURLOW STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2425989d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-269429</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospectus Supplement dated October 17,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(To Prospectus dated November 29, 2023)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="tm2425989d1_424b5img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>XORTX THERAPEUTICS
INC.</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement (this &ldquo;<B>Supplement</B>&rdquo;)
supplements and amends certain information contained in the prospectus dated November 29, 2023 (the &ldquo;<B>ATM Prospectus</B>&rdquo;),
relating to the offer and sale of our common shares through H.C. Wainwright &amp; Co., LLC (&ldquo;<B>Wainwright</B>&rdquo;), as sales
agent, in &ldquo;at the market offerings&rdquo; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, pursuant
to the At the Market Offering Agreement with Wainwright dated as of November 29, 2023 (the &ldquo;<B>Sales Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common shares are traded on The Nasdaq Capital
Market under the symbol &ldquo;XRTX&rdquo;. The last sale price of our common shares on October 16, 2024 was $2.17 per share
on The Nasdaq Capital Market. Under the ATM Prospectus, we initially registered up to $3,701,931 of our common shares for offer and sale
pursuant to the Sales Agreement. From November 29, 2023 through the date of this prospectus supplement, we have not sold any common shares
under the ATM Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of this Supplement is to suspend the
Sales Agreement and to terminate the continuous offering by us under the ATM Prospectus effective on October 17, 2024. We will
not make any sales of our common shares pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the
Securities and Exchange Commission; however, the Sales Agreement remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that we resume sales under the Sales
Agreement and we file a new prospectus supplement with the Securities and Exchange Commission in connection therewith, pursuant to General
Instruction I.B.5 of Form F-3, we will not sell our common shares in a primary public offering with a value exceeding more than one-third
of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period as long as the
aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates is less than $75,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this Supplement is October 17,
2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2425989d1_424b5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2425989d1_424b5img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 0$# 2(  A$! Q$!_\0
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MDF[(MT445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@
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M0-)U*>72]3U*XMBEM:;+:*WC(^^JY+$GK@#I5?2;+4)_%.N2VVJM:P1WR>9
M(482?(I/)Y&1QQ78VUNEK;16\>=D2!%SUP!BL2;PE;RZA<WD>HZG;/<.'D2W
MN-BDX Z8]!1[2[E?^M1NC91MT\_(;JI \:>'^?\ EG<_^@K3/!_WM?\ ^PO/
M_):TM8T&VUE(/.DN(9H&+13V\FQT)&#@^XJ;2=)MM'L_LUMO*EB[O(VYG8\E
MF/<FI<ER6ZE*G+VE^G_ ,GPK_P ??B'_ +"C_P#H"52TO_7^,/\ KNW_ **%
M=)8:9!ITEX\)<FZG,\FXY^8@#CVX%-L])M[*XOIH]Y:\D\R4,<C. ./P%-S5
MV_3] 5-V2[7_ !N86@ZC;67ACPU%/&7>Y1(HB #M;83DYZ< TFNP!M1N-2TB
MZ$>KZ?"#/$P.R:(Y8*WY'!'2KMAX/T[3[Z*YB>[=8"Q@@EF+1PD]=J]NII^K
M>%;+5KHW,DUW!*T?E2FWF*>:G]UAW')_.GS1YKID\E1PLT:&D7Z:II-K?HI5
M;B)9-I[9'2LB<_\ %Q+/_L&R_P#HQ:WK:VBL[6*V@0)%$@1%'8#@"J[:9 ^L
M1ZF=_GQPM !GY=I()X]>*S4DFWZFTHR<4NNAYSK*FS76-67.(M1GMIL?\\Y8
ME7GZ,%KH;[C2_!V?^?J#_P!%-6W-X<LI['4K.3S#%J$AEFYY#$ <<<?=%/O=
M L[[2(-.E\T1P;/*='VNC*,*P(Z&MW5B[?UT.58>2OY_YW'V>HVMSJ^H6443
M+/:^7YKE0 VY21@]^/6M($5F:1HEMH\<HA>:629]\LT[EW<XP,GV%6;&Q2PB
M>.-Y7#R-(3(VX@L<D?3GBN>7+?0ZX<UO>+=%%%2:!1110 4444 136T-Q&8Y
MXTD1NJNH8'\#6)-X(\.32%VT>R!/]VVC_P#B:**I2<=F2XI[HEM/"&@63[X=
M)L@_9OLT>1^(6ME4"C X'I112<G+=@HI;(=1112*"BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
